



TRIAMUNE

Each tablet contains:

Composition:

Nevirapine.....	200 mg
Lamivudine	150 mg
Stavudine.....	30 mg

Indications:

Progressive or advanced HIV infection, in combination with atleast 2 other antiretroviral drugs.

Description:

Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates.

Lamivudine is a cytosine analog. After lamivudine is triphosphorylated, it inhibits HIV reverse transcription via viral DNA chain termination and inhibits RNA- and DNA-dependent DNA polymerase activities of reverse transcriptase. The monophosphate form of lamivudine is incorporated into the viral DNA by hepatitis B virus polymerase, resulting in DNA chain termination.

Stavudine is an analog of thymidine. It is phosphorylated by cellular kinases into active triphosphate. Stavudine triphosphate inhibits the HIV reverse transcriptase by competing with natural substrate, thymidine triphosphate. It also causes termination of DNA synthesis by incorporating into it.

Simultaneous use of AZT is not recommended, as it can inhibit the intracellular phosphorylation of stavudine.

Other anti-HIV drugs do not possess this property.

Dosage :

Adult: 200mg once daily for first 14 days and if no rash appears increase to 200mg twice daily.

Children: 2 months-8 years: 4mg/kg once daily for first 14 days and then if no rash 7mg/kg twice daily

(maximum:400mg daily) 8-16 years (below 50kg): 4mg once daily for 1st 14 days and then if no rash, 4mg twice daily (maximum: 400mg daily) Over 50kg: Adult dose.

Presentations:

	MRP	Retailer	Stockist
30 tablets	615.50	492.40	443.16
60 tablets	629.50	503.60	453.24